Ansuvimab
Ansuvimab-zykl is a recombinant human monoclonal antibody medication used to treat infections caused by Zaire ebolavirus, the virus responsible for Ebola virus disease. It works by binding to and neutralizing the virus, helping the body's immune system combat the infection. This treatment is reserved for patients with confirmed or suspected Ebola virus infection under appropriate clinical settings.
A monoclonal antibody therapy for treating Zaire ebolavirus (Ebola) infections.
Key facts at a glance
- ATC
- J06BD04
- RxNorm
- 2472152
- Generic
- Ansuvimab
- Class
- atc-j06
- Brands
- Ebanga
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks, particularly in first trimester
regular fetal monitoring and ultrasound assessments
Use with caution and monitor for adverse effects.
pregnancy
second third trimesteruse only if benefits outweigh risks
may be used when benefits outweigh fetal risks, particularly for treatment of Ebola
regular fetal monitoring including ultrasound for growth assessment
Use with caution and monitor for adverse effects.
pediatric_age
neonates infantsweight-based dosing required
approved for use in pediatric patients including neonates for Ebola treatment
close monitoring of vital signs and potential infusion reactions
pediatric_age
children adolescentsweight-based dosing required
approved for use in pediatric patients for Ebola treatment
monitor for infusion-related reactions
geriatric
elderly 65 yearsno specific adjustment required
use with caution due to potential comorbidities and reduced immune function
close monitoring of renal function and infusion reactions
Use with caution and monitor for adverse effects.
renal_impairment
mild moderate severeno dosage adjustment required
no dose adjustment needed for renal impairment as monoclonal antibodies are not renally eliminated
standard monitoring for infusion reactions
hepatic_impairment
mild moderateno specific adjustment required
use with caution in hepatic impairment, monitor liver function tests
monitor liver function tests before and during treatment
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment required
monoclonal antibodies are not significantly excreted in breast milk, breastfeeding is generally considered compatible
no specific monitoring required
Statistics and clinical data
FDA approval year
First FDA approval for Ansuvimab-zykl (Ebanga)
Drug class
Therapeutic classification as antiviral agent
Indication
Therapeutic indication for adult and pediatric patients
Mechanism of action
Pharmacological mechanism of action
Treatment of infection caused by Zaire ebolavirus in adults and children.
Ansuvimab is a recombinant human monoclonal antibody that binds to the Ebola virus surface protein, neutralizing the virus and enabling the immune system to clear the infection.
This is a specialized antiviral therapy administered intravenously under healthcare professional supervision. Clinical benefit is greatest when administered early in the course of infection. Safety and effectiveness may be established through clinical trials and emergency use pathways given the serious nature of Ebola virus disease.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy